December 04th, 2025

Silver Spring, MD / CRWE PRESS RELEASE / December 3, 2025 - The U.S. Food and Drug Administration today granted approval for Avance (acellular nerve allograft-arwx) in surgical implantation. Avance is a peripheral nerve scaffold approved for sensory . Read more

October 24th, 2025

Las Vegas, NV  / CRWE PRESS RELEASE / October 24, 2025 — FOR IMMEDIATE RELEASE — Bondezz™, today announced the appointment of Brian Colando as Vice President of Sales. In this role, Brian Colando will oversee the development of. Read more

October 18th, 2023

Shares of Sage Therapeutics, Inc. (Nasdaq: SAGE), a leading biopharmaceutical company specializing in neurological and neuropsychiatric disorders, surged over 5% in pre-market trading after the company said that the U.S. Food and Drug Administration . Read more

October 02nd, 2023

Shares of Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) surged by more than 20% in pre-market trading following the company's decision to discontinue its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, designed for the treatment . Read more

September 26th, 2023

Shares of Profound Medical Corp. (Nasdaq: PROF) surged by more than 10% in after-hours trading after it announced FDA clearance for its Thermal Boost module in conjunction with TULSA-PRO, which allows surgeons to treat various prostate conditions, in. Read more

September 25th, 2023

Shares of Femasys Inc. (Nasdaq: FEMY) surged by over 100% in after-hours trading following the company's announcement of receiving 510(k) Clearance from the United States Food and Drug Administration (FDA) for its groundbreaking infertility treatment. Read more

September 20th, 2023

Shares of ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) plunged over 40% following the announcement that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for neffy (epinephrine na. Read more

September 15th, 2023

Shares of Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) surged over 10% after the U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) for lifileucel due to resource constraints. The new target action date is . Read more

September 13th, 2023

Semtech Corporation (Nasdaq: SMTC), a technology company specializing in semiconductor solutions, reported earnings of $0.11 per share for the second quarter of fiscal 2024, surpassing the consensus EPS estimate of $0.02. Quarterly sales for Semtech . Read more

September 13th, 2023

Shares of Spirit Airlines, Inc. (NYSE: SAVE) experienced a dip in pre-market trading as it revised downwardly its third-quarter 2023 outlook. The company now anticipates revenues between $1.245 billion and $1.255 billion, a notable decrease from its . Read more

September 12th, 2023

Shares of Avalo Therapeutics, Inc. (Nasdaq: AVTX) surged by more than 40% following the company's announcement of a purchase agreement with AUG Therapeutics, LLC (AUG), wherein it will sell its rights, assets, and interests related to the 800 Series . Read more

September 01st, 2023

Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products Washington D.C. / CRWE PRESS RELEASE / September 1, 2023 -   The Federal Tra. Read more

August 31st, 2023

Shares of 23andMe Holding Co. (Nasdaq: ME) surged over 5% in after-hours trading as the company announced an FDA 510(k) clearance to expand its Genetic Health Risk Report related to BRCA1/BRCA2 variants. This clearance now permits 23andMe to provide . Read more

August 30th, 2023

Shares of Outlook Therapeutics, Inc. (Nasdaq: OTLK) plummeted over 50% in pre-market trading following the company's announcement of receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics L. Read more

August 22nd, 2023

Shares of Fulcrum Therapeutics, Inc. (Nasdaq: FULC) surged over 30% in pre-market trading following the announcement that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for F. Read more